Clinical Trials Logo
  1. Home
  2. Metastatic Disease
  3. NCT04116164

Safety and Targeting of Anti-hk2 Antibody in mCRPC

Metastatic Disease Clinical Trial

Official title:
A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2 (hk2) in Subjects With Metastatic Castration-resistant Prostate Cancer.

Clinical Trial Summary

This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This imaging study will be conducted to confirm the safety and estimate the mass amount of antibody h11B6, and confirm in vivo tumor targeting of the antibody, using Indium-111 (111In) radiolabeled h11B6 in subjects with advanced prostate cancer. This study will also provide the dosimetric information crucial for Phase 1 therapy.

Clinical Trial Description

It is the intent to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This Phase 0 study will be conducted to confirm the safety, estimate the mass amount, and confirm in vivo tumor targeting of the antibody. This study will use Indium-111 (111In) radiolabeled h11B6 in subjects with mCRPC to image known sites of disease and identify a favorable mass amount of antibody for satisfactory tumor targeting with minimal/no accumulation off-target. In cohort 1, In-111 labeled h11B6 will remain fixed at 2 mg, and additional h11B6 will be added in 2 sub-cohorts (8 mg and 18 mg respectively); up to 6 patients may be entered into a sub-cohort. Additional patients (up to 6) will be studied once the most favorable mass and imaging time point have been established, to establish targeting of antibody to known disease. This study will provide the dosimetric information crucial for Phase 1 therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04116164
Study type Interventional
Source SpectronRX
Contact
Status Terminated
Phase Early Phase 1
Start date September 18, 2019
Completion date July 6, 2023
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01450683 - Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy Phase 2
Completed NCT04595032 - MAnagement of METastatic Disease In Campania (MAMETIC)
Terminated NCT01020305 - Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Phase 1/Phase 2
Withdrawn NCT02496832 - A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo N/A
Completed NCT01763970 - Stereotactic Radiation Therapy for Pediatric Sarcomas N/A
Completed NCT01703910 - Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic Phase 2
Completed NCT00609401 - Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) Phase 2
Completed NCT02628379 - Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
Completed NCT00480389 - Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal Phase 2
Recruiting NCT03632005 - Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery N/A
Recruiting NCT04492735 - The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
Terminated NCT02175654 - Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab Phase 2
Completed NCT01875380 - Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer Phase 2
Not yet recruiting NCT01861938 - Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Phase 2/Phase 3
Terminated NCT00532454 - Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen Phase 2
Terminated NCT02795819 - Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer Phase 1
Recruiting NCT05188911 - Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
Completed NCT03823989 - Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients Phase 1
Terminated NCT01904916 - CPCT-05 Biopsy Protocol Patient Selection N/A
Terminated NCT01484860 - Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy Phase 2